Daniel Savic, PhD
Daniel Savic, PhD

Daniel Savic, PhD

Assistant Member, St. Jude Faculty



PhD – The University of Chicago, Chicago, Illinois (2012)

Research Interests

My primary research focus involves studying gene regulatory architecture in order to address a fundamental and critical question concerning childhood leukemia: how does the non-coding portion of the human genome impact antileukemic drug resistance and disease relapse? Our laboratory is involved in three related areas of research:  

  • Role of non-coding, regulatory elements in antileukemic drug resistance and disease relapse
  • Functional characterization of non-coding DNA sequence variants associated with relapse and MRD in pediatric leukemia
  • Development of novel, high-throughput pharmacogenomic assays

Selected Publications

Ramaker RC*, Savic D*, Hardigan AA, Newberry K, Cooper GM, Myers RM, Cooper SJ.  A genome-wide interactome of DNA-associated proteins in the human liver. Genome Research Nov;27(11):1950-1960, 2017. *equal contributions

Chilsolm DA, Savic D, Moore AJ, Ballesteros-Tato A, Leon B, Crossman DK, Murre C, Myers RM, Weinmann AS.  CTCF translates IL-2- and αKG-sensitive metabolic changes in T cells into context-dependent differentiation gene programs. Immunity Aug 15;47(2):251-267, 2017.

Agee JM, Varley KE, Gertz J, Savic D, Roberts BS, Bailey SK, Shevde LA, Ramaker R, Lasseigne BN, Kirby MK, Newberry K, Partridge EC, Oliver PG, Sexton KG, Grizzle WE, Forero A, Buchsbaum DJ, Myers RM.  Genomic regulation of invasion by STAT3 in triple negative breast cancer.  Oncotarget Jan 31;8(5):8226-8238, 2017. 

Savic D, Ramaker RC, Roberts BS, Burwell TC, Dean EC, Meadows SK, Cooper SJ, Garabedian MJ, Gertz J, Myers RM. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Medicine Jul 11;8(1):74, 2016.

Engel KL, Mackiewicz M, Hardigan AA, Myers RM, Savic D. Decoding transcriptional enhancers: Evolution from annotation to functional interpretation. Seminars in Cellular and Developmental Biology Sep;57:40-50, 2016.

Savic D, Roberts BS, Carleston JB, Partridge EC, White MA, Cohen BA, Cooper GM, Gertz J, Myers RM. Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/enhancer-binding protein beta binding sites. Genome Research Dec;25(12):1791-800, 2015.

Savic D, Partridge EC, Newberry K, Smith S, Meadows S, Roberts BS, Mackiewicz M, Mendenhall E, Myers RM. CETCh-seq: CRISPR epitope tagging ChIP-seq of DNA-binding proteins. Genome Research Oct;25(10):1581-9,2015.

Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RKS, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics Jun;47(6):607-14, 2015.

Savic D, Gertz J, Jain P, Copper GM, Myers RM. Mapping genome-wide transcription factor binding sites in frozen tissues. Epigenetics & Chromatin 6(1):30, 2013.

Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, Cooper GM, Reddy TE, Crawford GE, Myers RM. Distinct properties of cell type-specific and shared transcription factor binding sites. Molecular Cell 52(1):25-36, 2013. Recommended by Faculty 1000.

Sakabe NJ**, Savic D**, Nobrega MA. Transcriptional enhancers in development and disease. Genome Biology 13(1):238, 2012. **equal contributions and corresponding authors

Savic D*, Ye H, Aneas I, Park SY, Bell GI, Nobrega MA.* Alterations in TCF7L2 expression define its role as a key regulator of glucose metabolism. Genome Research 21(9):1417-25, 2011. *corresponding authors

Last update: November 2017

For updates on COVID-19, please read.